Sentences with phrase «for ovarian cancer cell»

Not exact matches

Philippa Taylor explained why she thought it was an encouraging discovery: «There could be real benefits for some people, particularly young girls or people who are going through cancer treatment or chemotherapy and that destroys any chance of having their own eggs and growing eggs cells so if you can remove ovarian tissue, grow some egg cells outside the womb and implant them after the treatment then that could be very positive.»

«For this reason, we decided to combine vitamin C with a PARP inhibitor, a drug type known to cause cancer cell death by blocking the repair of DNA damage, and already approved for treating certain patients with ovarian cancer.&raqFor this reason, we decided to combine vitamin C with a PARP inhibitor, a drug type known to cause cancer cell death by blocking the repair of DNA damage, and already approved for treating certain patients with ovarian cancer.&raqfor treating certain patients with ovarian cancer.»

Then the researchers turned to the lab, where they exposed human liver, breast, colon, ovarian, and other cancer cells to the drugs, which appeared to make it easier for the cells to migrate.

«While the presence of lymphocytes in tumors is often associated with better clinical outcomes, this research adds clarity on the diversity of T cells within the tumor environment and their influence on ovarian cancer outcomes,» says first author Kunle Odunsi, MD, PhD, FRCOG, FACOG, Deputy Director, M. Steven Piver Professor and Chair of Gynecologic Oncology, and Executive Director of the Center for Immunotherapy at Roswell Park.

Immune therapy for ovarian, breast and colorectal cancer — treatments that encourage the immune system to attack cancer cells as the foreign invaders they are — has so far had limited success, primarily because the immune system often can't destroy the cancer cells.

The researchers treated 63 cancer cell lines (26 breast, 14 colorectal and 23 ovarian) with low - dose 5 - azacitidine (AZA), an FDA - approved drug for myelodysplastic syndrome, that reverses epigenetic changes by stripping off the methyl group that silences the gene.

EMT is important for cell migration and invasion — two characteristic of metastatic cancer cells — strongly suggesting that the link between lncRNAs and EMT contributes to the metastatic progression of ovarian cancer.

«For example, we found that highly aggressive ovarian cancer cells are glutamine - dependent, and in our laboratory studies, we showed that depriving such cells of external sources of glutamine — as some experimental drugs do — was an effective way to kill late - stage cells.

Now — in a paper published online April 17, 2018 in Cell Reports — Bandyopadhyay's lab has systematically mapped connections between 625 breast and ovarian cancer genes and nearly every FDA approved chemotherapy for breast or ovarian cancer.

The lab of co-author Dr. Robert Bast Jr., an expert in ovarian cancer and vice president for translational research at MD Anderson, inserted gel - bound carbon nanotubes into the ovaries of rodents to mimic the accumulations that are expected for nanotubes linked to special antibodies that recognize tumor cells.

The researchers then exposed cells from each of these lines to a panel of 31 different drug treatments — including 23 chemotherapy compounds approved by the FDA for breast and ovarian cancers, six targeted cancer drugs, and two common drug combinations.

They systematically deleted genes for secreted effector proteins — molecules that the parasite injects into a host cell to modulate the immune system during infection — and injected the altered parasites into mice with aggressive ovarian cancer.

Researchers at Rice University's Laboratory for Systems Biology of Human Diseases analyzed the metabolic profiles of hundreds of ovarian tumors and discovered a new test to determine whether ovarian cancer cells have the potential to metastasize.

In particular, it has been shown that cells with other HR repair pathway defects, such as BRCA mutations frequently found in breast and ovarian cancer, are sensitive to inhibition of the enzyme PARP, and the PARP inhibitor Olaparib has been approved for treatment of BRCA - mutated ovarian cancers.

For the new study, described in the October 23rd issue of Nature Communications, scientists at the Johns Hopkins Kimmel Cancer Center and Dana Farber Cancer Institute in Boston collected tissue samples containing normal cells, ovarian cancers, metastases that had spread elsewhere, and small cancers found in the fallopian tubes, which included single cell layers of cancer called «p53 signatures» and serous tubal intraepithelial carcinoma, or STIC leCancer Center and Dana Farber Cancer Institute in Boston collected tissue samples containing normal cells, ovarian cancers, metastases that had spread elsewhere, and small cancers found in the fallopian tubes, which included single cell layers of cancer called «p53 signatures» and serous tubal intraepithelial carcinoma, or STIC leCancer Institute in Boston collected tissue samples containing normal cells, ovarian cancers, metastases that had spread elsewhere, and small cancers found in the fallopian tubes, which included single cell layers of cancer called «p53 signatures» and serous tubal intraepithelial carcinoma, or STIC lecancer called «p53 signatures» and serous tubal intraepithelial carcinoma, or STIC lesions.

The research, «Synchrotron X-Ray Fluorescence Nanoprobe Reveals Target Sites for Organo - Osmium Complex in Human Ovarian Cancer Cells», is published in Chemistry — A European Journal.

Top honors for both the 17 - to 18 - year - old category and the grand prize went to Shree Bose, who discovered that an energy protein of the cell, AMP kinase, plays a role in developing resistance to a drug commonly used to treat ovarian cancer.

They found that tumor cells with the mutant genes were particularly sensitive to a drug, olaparib, recently approved for the treatment of hereditary ovarian cancer.

Those findings are among results of six studies of investigational chimeric antigen receptor (CAR) T cells for both adult and pediatric leukemias, adult lymphomas, and ovarian cancer which will be presented during the 2016 American Society of Clinical Oncology Annual Meeting.

Led by Ludwig Lausanne investigator Alexandre Harari and George Coukos, director of the Ludwig Institute for Cancer Research, Lausanne, the study shows that ovarian tumors harbor highly reactive killer T cells — which kill infected and cancerous cells — and demonstrates how they can be identified and selectively grown for use in personalized, cell - based immunotherapies.

Ongoing Phase 1b / 2 clinical trials combine entinostat with KEYTRUDA ® from Merck & Co., Inc. for non-small cell lung cancer, melanoma and colorectal cancer; with TECENTRIQ ® from Genentech, Inc. for triple negative breast cancer; and with BAVENCIO ® from Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.

While the abdominal area is the main site for ovarian cancer spread, the intravenous route of chemotherapy is needed to catch cancer cells that may have spread outside the abdomen.

David Lampi Hermanson, Ph.D., a 2014 - 2017 CRI postdoctoral fellow at the University of Minnesota, is investigating the use of natural killer (NK) cell - based immunotherapy for ovarian cancer.

There, in a quest to develop targeted therapies for ovarian cancer, she began studying necroptosis, a form of programmed cell death.

Several phase I and II trials of adoptive T cell transfer techniques are currently under way for patients with ovarian cancer, including:

Juan R. Cubillos - Ruiz, Ph.D., a 2012 - 2014 CRI postdoctoral fellow at Weill Cornell Medical College, is working to understand how dendritic cells (DCs), immune cells responsible for activating and «training» other immune cells, acquire pro-tumor properties in ovarian cancer.

Current immunotherapies for ovarian cancer fall into six broad categories: monoclonal antibodies; checkpoint inhibitors and immune modulators; therapeutic vaccines; adoptive T cell transfer; oncolytic viruses; and adjuvant immunotherapies.

Tanyi said he is eager to explore whether the dendritic - cell vaccine might also be used as a first - line treatment for women who are newly diagnosed with ovarian cancer.

$ 1.8 M Supports Cancer Drug Discovery on Commonly Mutated Gene New Brunswick Patch — April 5, 2016 Behavioral Scientist Shares Insights about FDA's Proposed Rule on Banning Tanning Bed Use among Minors News-Medical.net - March 19, 2016 Intervention Program Reduces Caregiver Distress during Hospitalization of Pediatric Stem Cell Transplant Patients News-Medical.net - March 9, 2016 Exploring Genomic Pathways in the Development of Ovarian Cancer GMNews.com - March 2, 2016 Differences in Type of Small Protein may further Elucidate Lung Cancer Risk in African Americans ScienceDaily.com - March 2, 2016 Study Looks at Post-Treatment Resources for Prostate Cancer Patients Transitioning to Survivorship News-Medical.net - February 11, 2016 Drawing the Line on Tanning Bed Use by Teens ScienceDaily.com - December 21, 2015 What Rutgers Study Uncovered about E-Cigarette Use NJBiz.com - December 9, 2015 Identification of Barrier that Prevents Progression of Benign Kidney Tumors to Malignant Disease MedicalNewsToday.com - November, 24, 2015 What is the Color of the Lung Cancer Ribbon?

The Xie Lab demonstrated that differentiation - defective Drosophila ovarian germline stem cells (GSCs), behaving like human cancer stem cells, can out - compete normal stem cells for a position in the niche.

The FDA - approved antihelminthic drug, pyrvinium pamoate (PPAM), was found in a screening for compounds that promoted β - catenin turnover and, thereby, inhibiting Wnt signaling in ovarian and other cancer cells (Table 1)[51, 56].

Coukos, who is currently leading an ovarian cancer clinical trial sponsored by CRI's Clinical Accelerator, sought to understand why PD - 1 / PD - L1 immunotherapies are often ineffective for these patients, even though ovarian tumors are often infiltrated by «killer» T cells that recognize tumor - specific neoantigens and express high levels of PD - 1.

Review of «Induced Pluripotent Stem Cell - Derived Natural Killer Cells for Treatment of Ovarian Cancer» from Stem Cells by Stuart P. Atkinson

Induced Pluripotent Stem Cell - Derived Natural Killer Cells for Treatment of Ovarian Cancer.

Now — in a paper published online April 17, 2018 in Cell Reports — Bandyopadhyay's lab has systematically mapped connections between 625 breast and ovarian cancer genes and nearly every FDA - approved chemotherapy for breast or ovarian cancer.

He is the principal investigator of an NCI - funded, multi-million-dollar Specialized Program of Research Excellence (SPORE) in ovarian cancer, and he is the principal investigator of a multi-million-dollar grant from the New York State Stem Cell Science program (NYSTEM) to pioneer a novel strategy of reprogramming human mature T cells and hematopoietic stem cells for generating sustained attack against ovarian cancer in patients.

a. Mechanism - guided therapeutic strategies for genetic alterations that affect the SWI / SNF chromatin remodeling complex in epithelial ovarian cancer (such as ARID1A mutation in clear cell and endometrioid subtypes of ovarian cancer, and CARM1 amplification / overexpression in high - grade serous ovarian cancer).

Their three - dimensional cell - culture system, adapted for high - throughput screening, has enabled them to identify small molecules that can inhibit adhesion and invasion, preventing ovarian cancers from spreading to nearby tissues.

The first step was to understand the biological signals that attract ovarian cancer cells to the omentum and use it for rapid growth.

The good news is that if markers for these tubal cells can be found, then blood tests, advanced Pap smears, or direct tests on tubal tissue might spot ovarian cancer earlier, the study authors said.

For the study, Levine and his colleagues performed genetic analyses of ovarian cancer cells from 96 patients.